Verona Pharma COPD Awareness 2021 Ensifentrine Therapy

Verona Pharma presented an overview of ensifentrine, a Phase 3 first-in-class dual PDE3/PDE4 inhibitor for maintenance treatment of COPD. The presentation highlights a ~$10.5B US market with significant unmet need, demonstrating efficacy in two large Phase 2b trials with a safety profile consistent with placebo.